Radiation/immunotherapy combo shows promise for recurrent/metastatic head and neck cancers
(American Society for Radiation Oncology) A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination of radiation and pembrolizumab may offer a new treatment option for patients who are ineligible for cisplatin chemotherapy, part of standard treatment for the disease. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news
Drug used for breast, kidney cancers may also extend survival for head and neck cancers
(American Society for Radiation Oncology) A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment. Patients enrolled in a randomized phase II trial who received the mTOR inhibitor everolimus were more likely to be cancer-free a year after therapy than those who took a placebo, and the benefit persisted for those with mutations in their TP53 gene. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news
Head and neck cancer: The hidden sign in a person’s ear that should never be ignored
HEAD AND NECK cancers include cancers in the larynx, throat, lips, mouth, nose and salivary glands. Spotting the early signs of the deadly condition is vital and noticing a certain feeling in your ears could be an early warning. (Source: Daily Express - Health)
Source: Daily Express - Health - February 24, 2020 Category: Consumer Health News Source Type: news
Cancer symptoms: Survivor details the little known signs of head and neck cancer
CANCER is a physically and emotionally devastating disease. One survivor wants to share his story to raise awareness and to help people become familiar with the symptoms. (Source: Daily Express - Health)
Source: Daily Express - Health - February 21, 2020 Category: Consumer Health News Source Type: news
FDA grants priority review to Roche ’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanc ed non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing. The FDA is expected to make a decision on approval by June 19, 2020.“In the IMpower110 study, Tecentriq alone demo...
Source: Roche Investor Update - February 19, 2020 Category: Pharmaceuticals Source Type: news
FDA grants priority review to Roche ’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanc ed non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing. The FDA is expected to make a decision on approval by June 19, 2020.“In the IMpower110 study, Tecentriq alone demo...
Source: Roche Media News - February 19, 2020 Category: Pharmaceuticals Source Type: news
FDA Grants 2 Fast Track Designations for ALX148
The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news
China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news
Absent p53, oral cancers recruit and reprogram nerves to fuel tumor growth
(University of Texas M. D. Anderson Cancer Center) Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2020 Category: Cancer & Oncology Source Type: news
TAT 2020 Honorary Award: A recognition in cancer drug development to Lillian Siu
(European Society for Medical Oncology) The European Society for Medical Oncology is pleased to announce that Lillian L. Siu, Professor at the University of Toronto and Medical Oncologist at the Princess Margaret Cancer Centre, Toronto, will receive the TAT 2020 Honorary Award in recognition of her pivotal contributions in the development of new anticancer drugs, particularly with respect to phase I trials in head and neck malignancies. The award will be presented during the ESMO Targeted Anticancer Therapies Congress, to be held in Paris, France, March 2-4. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2020 Category: International Medicine & Public Health Source Type: news
Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survi...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news
Botanical drug is shown to help patients with head and neck cancers
In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck. APG-157 is made up of multiple compounds produced by plants, including curcumin. UCLA Jonsson Comprehensive Cancer Center researchers found that treatment with this botanical drug resulted in (Source: World Pharma News)
Source: World Pharma News - February 6, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Gaps in cure rate appear linked to race and insurance status for common HPV-related cancer
(National Comprehensive Cancer Network) Largest population-based analysis to date on outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) finds significant racial and socioeconomic disparities, according to new research in JNCCN-Journal of the National Comprehensive Cancer Network. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 6, 2020 Category: Cancer & Oncology Source Type: news
Botanical drug is shown to help patients with head and neck cancers
(University of California - Los Angeles Health Sciences) In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2020 Category: International Medicine & Public Health Source Type: news
